By Dean Seal


Compass Therapeutics said regulators have granted fast-track designation to its CTX-009 antibody in combination with paclitaxel for the treatment of biliary tract cancer.

The...

Related Keywords

Thomas Schuetz , Drug Administration , Dean Seal , Dow Jones , Markets ,